Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Accumulated Expenses: 2024-2025

Historic Other Accumulated Expenses for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $6.3 million.

  • Kura Oncology's Other Accumulated Expenses rose 154.21% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 154.21%. This contributed to the annual value of $2.7 million for FY2024, which is N/A change from last year.
  • Per Kura Oncology's latest filing, its Other Accumulated Expenses stood at $6.3 million for Q3 2025, which was up 38.81% from $4.5 million recorded in Q2 2025.
  • Kura Oncology's Other Accumulated Expenses' 5-year high stood at $6.3 million during Q3 2025, with a 5-year trough of $1.8 million in Q2 2024.
  • For the 2-year period, Kura Oncology's Other Accumulated Expenses averaged around $3.6 million, with its median value being $3.5 million (2025).
  • Within the past 5 years, the most significant YoY rise in Kura Oncology's Other Accumulated Expenses was 154.36% (2025), while the steepest drop was 5.04% (2025).
  • Kura Oncology's Other Accumulated Expenses (Quarterly) stood at $2.7 million in 2024, then spiked by 154.21% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, $4.5 million for Q2 2025, and $3.5 million during Q1 2025.